We are live on ! Find out more
SFM

Sphera Funds Management Portfolio holdings

AUM $630M
1-Year Est. Return 108.65%
This Fund
S&P 500
This Quarter Est. Return
+19.88%
1 Year Est. Return
+108.65%
3 Year Est. Return
+217.64%
5 Year Est. Return
+342.91%
10 Year Est. Return
+2,254.45%
AUM
$1.1B
AUM Growth
+$208M
Cap. Flow
+$144M
Cap. Flow %
13.12%
Top 10 Hldgs %
54.38%
Holding
136
New
36
Increased
27
Reduced
26
Closed
32

Top Buys

Rank Stock Value
1
JNJ icon
Johnson & Johnson
JNJ
+$35.5M
2
NVO
Novo Nordisk
NVO
+$19.7M
3
URGN icon
UroGen Pharma
URGN
+$12.9M
4
BMY icon
Bristol-Myers Squibb
BMY
+$12.4M
5
ICPT
Intercept Pharmaceuticals, Inc.
ICPT
+$10.9M

Top Sells

Rank Stock Value
1
VTRS icon
Viatris
VTRS
+$19.7M
2
CELG
Celgene Corp
CELG
+$18.8M
3
ITRN icon
Ituran Location and Control
ITRN
+$14.6M
4
RETA
Reata Pharmaceuticals, Inc. Class A Common Stock
RETA
+$11.6M
5
TEVA icon
Teva Pharmaceuticals
TEVA
+$11.5M

Sector Composition

Rank Sector Weight
1 Healthcare 55.27%
2 Technology 6.57%
3 Consumer Discretionary 1.18%
4 Industrials 1.08%
5 Communication Services 0.54%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
MGIC
101
DELISTED
Magic Software Enterprises
MGIC
$324K 0.03%
+38,784
New +$323K
BNTC icon
102
Benitec Biopharma
BNTC
$402M
$228K 0.02%
471
– –
CLRB icon
103
Cellectar Biosciences
CLRB
$20.5M
$206K 0.02%
292
– –
ABEO icon
104
Abeona Therapeutics
ABEO
$366M
– –
-10,801
Closed -$1.93M
ACIU icon
105
AC Immune
ACIU
$223M
– –
-310,613
Closed -$2.94M
ADVM
106
DELISTED
Adverum Biotechnologies
ADVM
– –
-6,336
Closed -$200K
AGIO icon
107
Agios Pharmaceuticals
AGIO
$1.79B
– –
-67,500
Closed -$3.11M
ALLO icon
108
Allogene Therapeutics
ALLO
$649M
– –
-113,437
Closed -$3.06M
APLS
109
DELISTED
Apellis Pharmaceuticals
APLS
– –
-117,000
Closed -$1.54M
CLSD
110
DELISTED
Clearside Biomedical
CLSD
– –
-79,008
Closed -$1.27M
EVOK
111
DELISTED
Evoke Pharma
EVOK
– –
-9,798
Closed -$3.5M
ITRN icon
112
Ituran Location and Control
ITRN
$1.09B
– –
-122,177
Closed -$14.6M
KZR
113
DELISTED
Kezar Life Sciences
KZR
– –
-2,000
Closed -$472K
LRMR icon
114
Larimar Therapeutics
LRMR
$397M
– –
-31,667
Closed -$1.88M
SAGE
115
DELISTED
Sage Therapeutics
SAGE
– –
-103,500
Closed -$9.91M
SAGE
116
PUT
DELISTED
Sage Therapeutics
SAGE
– –
-24,500
Closed -$2.35M
SGMO
117
DELISTED
SANGAMO THERAPEUTICS INC
SGMO
– –
-340,000
Closed -$3.9M
SRRK icon
118
Scholar Rock
SRRK
$5.67B
– –
-175,511
Closed -$4.03M
SVRA icon
119
Savara
SVRA
$1.12B
– –
-110,000
Closed -$833K
VKTX icon
120
Viking Therapeutics
VKTX
$3.7B
– –
-745,727
Closed -$5.71M
VRCA icon
121
Verrica Pharmaceuticals
VRCA
$89.7M
– –
-9,700
Closed -$791K
XBI icon
122
State Street SPDR S&P Biotech ETF
XBI
$9.95B
– –
-45,000
Closed -$3.83M
PVLA
123
Palvella Therapeutics
PVLA
$1.99B
– –
-8,750
Closed -$1.86M
WHWK
124
Whitehawk Therapeutics
WHWK
$190M
– –
-75,455
Closed -$1.92M
ACGN
125
DELISTED
Aceragen Inc
ACGN
– –
-26,236
Closed -$1.23M
2 3 4
5
6

Similar funds

VIM
Vancity Investment Management Vancouver, British Columbia, Canada $629M AUM 2.49% 1-Year Est. Return
KCMH
Keywise Capital Management (HK) Hong Kong $630M AUM 81.01% 1-Year Est. Return
FCFC
First Commonwealth Financial Corp Indiana, Pennsylvania $629M AUM 20.47% 1-Year Est. Return
BI
BlueSpruce Investments Chicago, Illinois $631M AUM 11.83% 1-Year Est. Return
PWW
Pettyjohn Wood & White Lynchburg, Virginia $628M AUM 20.96% 1-Year Est. Return
TTSTC
Texas Treasury Safekeeping Trust Company Austin, Texas $628M AUM 15.58% 1-Year Est. Return
SWP
Summit Wealth Partners Orlando, Florida $632M AUM 9.71% 1-Year Est. Return
EIM
Essex Investment Management Boston, Massachusetts $632M AUM 95.36% 1-Year Est. Return

Sphera Funds Management's Q1 2019 Portfolio in Review

As of Q1 2019, Sphera Funds Management held 136 positions worth $1.1B, up 23% from $887M the previous quarter. Its ten largest holdings account for 54% of the portfolio.

Sphera Funds Management deployed $144M of net new capital in Q1 2019, opening 36 new positions and adding to 27 existing holdings. Its largest new stake was Johnson & Johnson: 265,000 shares worth $37M.

By sector, the portfolio is most concentrated in Healthcare at 55% of assets, down from 60% a quarter earlier, followed by Technology and Consumer Discretionary.

On the sell side, the largest reduction was Viatris, an estimated $19.7M trimmed.

  • Sphera Funds Management's largest Q1 2019 buy was Johnson & Johnson: 265,000 shares worth $37M.
  • Sphera Funds Management added most to Bristol-Myers Squibb in Q1 2019, an estimated $12.4M increase.
  • Sphera Funds Management's biggest Q1 2019 reduction was Viatris, cutting an estimated $19.7M.
  • Sphera Funds Management fully exited Ituran Location and Control in Q1 2019, selling an estimated $14.6M.
  • Sphera Funds Management's ten largest holdings make up 54% of its $1.1B portfolio in Q1 2019.
  • Sphera Funds Management opened 36 new positions and closed 32 in Q1 2019.
  • Sphera Funds Management's portfolio value rose 23% quarter-over-quarter to $1.1B.

Based on Sphera Funds Management's 13F filing for Q1 2019, filed 15 May 2019.